Moleculin Biotech (MBRX) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS
Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings data on Monday. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05), Fidelity Earnings reports.
Moleculin Biotech stock traded up $0.01 during midday trading on Wednesday, reaching $1.22. The stock had a trading volume of 785,948 shares, compared to its average volume of 2,600,803. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15. The firm has a market capitalization of $41.95 million, a price-to-earnings ratio of -2.39 and a beta of 2.26.
Several research firms have recently weighed in on MBRX. Maxim Group reissued a “buy” rating and issued a $3.00 price objective on shares of Moleculin Biotech in a research report on Wednesday, February 20th. ValuEngine lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, Zacks Investment Research lowered Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 14th.
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
See Also: Dividend Aristocrat Index
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.